Trials / Terminated
TerminatedNCT00699296
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
A Phase II Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety, efficacy and pharmacokinetics of oral LBH589 in Japanese adult patients with refractory cutaneous T-Cell Lymphoma and adult T-cell leukemia/lymphoma. LBH589 is administered orally once a day for three days per week.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panobinostat (LBH589) | 20mg/day p.o. on three times-a- week |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-12-01
- First posted
- 2008-06-17
- Last updated
- 2012-11-27
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00699296. Inclusion in this directory is not an endorsement.